Jul
2001

Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.

Jurlander B, Thim L, Klausen NK, et al.
Semin Thromb Hemostasis 2001;27(4):373-383.
NATA Rating :
Review by : M. Aldouri
NATA Review
A good overall review on the
characterization, mechanism of action, and preclinical and current clinical
evidence for the efficacy and safety of rFVIIa.

– M. Aldouri.